Latest & greatest articles for hiv

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hiv or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hiv and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hiv

21. BHIVA and BIA guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis

BHIVA and BIA guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis British HIV Association and British Infection Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis 2019 > > British HIV Association and British Infection Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management (...) of Candidiasis 2019 Introduction Advances in the treatment of HIV infection with antiretroviral therapy have led to dramatic reductions in opportunistic infections and death. However, late presentation of HIV remains a problem and is a significant contributory cause of death in people living with HIV in the UK. Individuals who are lost to follow-up or who are not able to adhere to antiretroviral therapy long term can also present with opportunistic infection. In addition, an increasing number of people

2019 British HIV Association

22. British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis

British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis (2019) Guideline Development Group: Cara Saxon (Lead Author), Anne Edwards, Riina Rautemaa- Richardson, Caroline Owen, Bavithra Nathan, Bret Palmer, Clare Wood, Humera Ahmed, Sameena Ahmad, Patient Representatives, Mark FitzGerald (CEG Editor) Clinical Effectiveness Group (...) (CEG), British Association for Sexual Health and HIV (BASHH) NEW IN THE 2019 GUIDELINES Terminology: • The new guidelines refer to ‘acute’ and ‘recurrent’ vulvovaginal candidiasis (VVC) and no longer use the terms ‘uncomplicated’ and ‘complicated’ VVC; the new definitions are felt to be more reflective of how women with VVC typically present to clinical services and are subsequently managed • The elements of complicated VVC where single dose treatments are not always appropriate are still covered

2019 British Association for Sexual Health and HIV

23. Dolutegravir lamivudine (Dovato) - human immunodeficiency virus type 1 (HIV-1)

Dolutegravir lamivudine (Dovato) - human immunodeficiency virus type 1 (HIV-1) Published 9 September 2019 1 Product update SMC2205 dolutegravir 50mg / lamivudine 300mg film-coated tablets (Dovato®) ViiV Healthcare Ltd 9 August 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated (...) submission dolutegravir / lamivudine (Dovato®) is accepted for use within NHSScotland. Indication under review: for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. In patients for whom this two-drug combination regimen is appropriate dolutegravir / lamivudine (Dovato®) offers a single tablet at no additional cost compared

2019 Scottish Medicines Consortium

24. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. Full Text available with Trip Pro

Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. An efavirenz-based regimen (with a 600-mg dose of efavirenz, known as EFV600) was the World Health Organization preferred first-line treatment for human immunodeficiency virus type 1 (HIV-1) infection until June 2018. Given concerns about side effects, dolutegravir-based and low-dose efavirenz-based combinations have been considered as first-line treatments for HIV-1 in resource-limited settings.We conducted (...) an open-label, multicenter, randomized, phase 3 noninferiority trial in Cameroon. Adults with HIV-1 infection who had not received antiretroviral therapy and had an HIV-1 RNA level (viral load) of at least 1000 copies per milliliter were randomly assigned to receive either dolutegravir or the reference treatment of low-dose efavirenz (a 400-mg dose, known as EFV400), combined with tenofovir and lamivudine. The primary end point was the proportion of participants with a viral load of less than 50

2019 NEJM Controlled trial quality: predicted high

25. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. Full Text available with Trip Pro

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. Two drugs under consideration for inclusion in antiretroviral therapy (ART) regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF). There are limited data on their use in low- and middle-income countries.We conducted a 96-week, phase 3, investigator-led, open-label, randomized trial in South Africa, in which we compared a triple-therapy combination (...) of emtricitabine (FTC) and DTG plus either of two tenofovir prodrugs - TAF (TAF-based group) or tenofovir disoproxil fumarate (TDF) (TDF-based group) - against the local standard-of-care regimen of TDF-FTC-efavirenz (standard-care group). Inclusion criteria included an age of 12 years or older, no receipt of ART in the previous 6 months, a creatinine clearance of more than 60 ml per minute (>80 ml per minute in patients younger than 19 years of age), and an HIV type 1 (HIV-1) RNA level of 500 copies or more

2019 NEJM Controlled trial quality: uncertain

26. Antiretroviral treatment can reduce the risk of HIV transmission between male partners to 'zero'. (Abstract)

Antiretroviral treatment can reduce the risk of HIV transmission between male partners to 'zero'. The studyA Rodger, V Cambiano, T Bruun, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet 2019;393:2428-38.This project was funded by the NIHR Research for Patient Benefit Programme (project number PB-PG-1013 (...) -32069).To read the full NIHR Signal, go to https://discover.dc.nihr.ac.uk/content/signal-000785/antiretroviral-treatment-can-reduce-the-risk-of-hiv-transmission-between-male-partners-to-zero.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

2019 BMJ

27. Emtricitabine, Ripivirine, Tenofovir Alafenamide (Odefsey) - HIV

Emtricitabine, Ripivirine, Tenofovir Alafenamide (Odefsey) - HIV Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf

2019 Health Canada - drugs and medical devices

28. Maintaining and improving quality of care within HIV clinical services

and human rights gaps remain: key populations are underserved, experience persistent stigma and discrimination and are subject to criminalization, violence and other human rights abuses (2). To address these gaps and reach global targets, HIV programmes must establish and maintain systems for ensuring a high level of quality in service delivery, within the framework of universal health coverage and supported by national quality policies and strategies. Three seminal 2018 publications (1,3,4) have (...) , district and facility levels and are people-centred. Delivery of quality services depends on all the building blocks of health systems, including optimized management, funding, human resources for health, information systems and procurement of high-quality drugs, laboratory supplies and commodities. In accordance with the 2016 WHO consolidated HIV treatment guidelines (7), quality HIV services should: • provide people-centred care; • offer safe, acceptable and appropriate clinical and non- clinical

2019 World Health Organisation HIV Guidelines

29. Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART). Full Text available with Trip Pro

Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART). A universal testing and treatment strategy is a potential approach to reduce the incidence of human immunodeficiency virus (HIV) infection, yet previous trial results are inconsistent.In the HPTN 071 (PopART) community-randomized trial conducted from 2013 through 2018, we randomly assigned 21 communities in Zambia and South Africa (total population, approximately 1 million) to group A (combination prevention (...) intervention with universal antiretroviral therapy [ART]), group B (the prevention intervention with ART provided according to local guidelines [universal since 2016]), or group C (standard care). The prevention intervention included home-based HIV testing delivered by community workers, who also supported linkage to HIV care and ART adherence. The primary outcome, HIV incidence between months 12 and 36, was measured in a population cohort of approximately 2000 randomly sampled adults (18 to 44 years

2019 NEJM Controlled trial quality: predicted high

30. HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa. Full Text available with Trip Pro

HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa. Universal antiretroviral therapy (ART) with annual population testing and a multidisease, patient-centered strategy could reduce new human immunodeficiency virus (HIV) infections and improve community health.We randomly assigned 32 rural communities in Uganda and Kenya to baseline HIV and multidisease testing and national guideline-restricted ART (control group) or to baseline testing plus annual testing (...) , eligibility for universal ART, and patient-centered care (intervention group). The primary end point was the cumulative incidence of HIV infection at 3 years. Secondary end points included viral suppression, death, tuberculosis, hypertension control, and the change in the annual incidence of HIV infection (which was evaluated in the intervention group only).A total of 150,395 persons were included in the analyses. Population-level viral suppression among 15,399 HIV-infected persons was 42% at baseline

2019 NEJM Controlled trial quality: predicted high

31. Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. Full Text available with Trip Pro

Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. The feasibility of reducing the population-level incidence of human immunodeficiency virus (HIV) infection by increasing community coverage of antiretroviral therapy (ART) and male circumcision is unknown.We conducted a pair-matched, community-randomized trial in 30 rural or periurban communities in Botswana from 2013 to 2018. Participants in 15 villages in the intervention group received HIV testing (...) and counseling, linkage to care, ART (started at a higher CD4 count than in standard care), and increased access to male circumcision services. The standard-care group also consisted of 15 villages. Universal ART became available in both groups in mid-2016. We enrolled a random sample of participants from approximately 20% of households in each community and measured the incidence of HIV infection through testing performed approximately once per year. The prespecified primary analysis was a permutation test

2019 NEJM Controlled trial quality: uncertain

32. Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials. Full Text available with Trip Pro

Quadruple versus triple combination antiretroviral therapies for treatment naive people with HIV: systematic review and meta-analysis of randomised controlled trials. To evaluate the effects of four drug (quadruple) versus three drug (triple) combination antiretroviral therapies in treatment naive people with HIV, and explore the implications of existing trials for clinical practice and research.Systematic review and meta-analysis of randomised controlled trials.PubMed, EMBASE, CENTRAL, Web (...) of Science, and the Cumulative Index to Nursing and Allied Health Literature from March 2001 to December 2016 (updated search in PubMed and EMBASE up to June 2018); and reference lists of eligible studies and related reviews.Randomised controlled trials comparing quadruple with triple combination antiretroviral therapies in treatment naive people with HIV and evaluating at least one effectiveness or safety outcome.Outcomes of interest included undetectable HIV-1 RNA, CD4 T cell count, virological failure

2019 BMJ

33. Management of newborns born to women with HIV (Human Immunodeficiency Virus) infection

Management of newborns born to women with HIV (Human Immunodeficiency Virus) infection Management of newborns born to women with HIV (Human Immunodeficiency Virus) infection Document ID CHQ-GDL-01243 Version no. 3.1 Approval date 28/05/2019 Executive sponsor Executive Director Medical Services Effective date 28/05/2019 Author/custodian Infectious Diseases Physician - Infection Management and Prevention services Review date 28/05/2021 Supercedes 3.0 Applicable to All Children’s Health Queensland (...) staff Authorisation Executive Director Clinical Services (QCH) Purpose This guideline provides best practice recommendations for obstetricians, paediatricians, neonatologists and Human Immunodeficient Virus (HIV) physicians regarding management of infants born to women with HIV infection. Scope This Guideline provides information for all Children’s Health Queensland (CHQ) employees (permanent, temporary and casual) and all organisations and individuals acting as its agents (including Visiting

2019 Queensland Health

34. Emtricitabine + tenofovir disoproxil (Truvada and other brands) for prevention of HIV infection in adolescents

Emtricitabine + tenofovir disoproxil (Truvada and other brands) for prevention of HIV infection in adolescents Prescrire IN ENGLISH - Spotlight ''Emtricitabine + tenofovir disoproxil (Truvada° and other brands) for prevention of HIV infection in adolescents'', 1 July 2019 {1} {1} {1} | | > > > Emtricitabine + tenofovir disoproxil (Truvada° and other brands) for prevention of HIV infection in adolescents Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |  (...)  |   |   |   |   |   |   |   |  Spotlight In the July-August issue of Prescrire International: emtricitabine + tenofovir disoproxil (Truvada° and other brands) for prevention of HIV infection in adolescents FREE DOWNLOAD Based on extrapolation of the data obtained in adults, the emtricitabine + tenofovir disoproxil combination (Truvada° or other brands) appears worth offering to adolescents whose sex practices place them at particularly

2019 Prescrire

35. Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services

Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services | The Ontario HIV Treatment Network The Ontario HIV Treatment Network Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services Strategies to link people with undiagnosed HIV infection to HIV testing, care, and prevention services , , , , Questions (...) What strategies have been successful at linking people with undiagnosed HIV infection to HIV testing, care, and prevention services? Key take-home messages A variety of strategies have shown promise for identifying individuals with undiagnosed HIV and engaging them with HIV testing using clinical, community-based, network-based, and self-directed approaches. Various service delivery models for implementing rapid initiation of antiretroviral treatment have demonstrated benefits for linking the newly

2019 Ontario HIV Treatment Network

36. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Full Text available with Trip Pro

·7% of 5119) community controls without HIV infection. Wheezing was present in 555 (31·7%) of 1752 cases (range by site 10·6-97·3%). 30-day case-fatality ratio was 6·4% (114 of 1769 cases). Blood cultures were positive in 56 (3·2%) of 1749 cases, and Streptococcus pneumoniae was the most common bacteria isolated (19 [33·9%] of 56). Almost all cases (98·9%) and controls (98·0%) had at least one pathogen detected by PCR in the NP-OP specimen. The detection of respiratory syncytial virus (RSV (...) ), parainfluenza virus, human metapneumovirus, influenza virus, S pneumoniae, Haemophilus influenzae type b (Hib), H influenzae non-type b, and Pneumocystis jirovecii in NP-OP specimens was associated with case status. The aetiology analysis estimated that viruses accounted for 61·4% (95% credible interval [CrI] 57·3-65·6) of causes, whereas bacteria accounted for 27·3% (23·3-31·6) and Mycobacterium tuberculosis for 5·9% (3·9-8·3). Viruses were less common (54·5%, 95% CrI 47·4-61·5 vs 68·0%, 62·7-72·7

2019 Lancet

37. Rapid initiation of antiretroviral therapy for people living with HIV. Full Text available with Trip Pro

Rapid initiation of antiretroviral therapy for people living with HIV. Despite antiretroviral therapy (ART) being widely available, HIV continues to cause substantial illness and premature death in low-and-middle-income countries. High rates of loss to follow-up after HIV diagnosis can delay people starting ART. Starting ART within seven days of HIV diagnosis (rapid ART initiation) could reduce loss to follow-up, improve virological suppression rates, and reduce mortality.To assess the effects (...) of interventions for rapid initiation of ART (defined as offering ART within seven days of HIV diagnosis) on treatment outcomes and mortality in people living with HIV. We also aimed to describe the characteristics of rapid ART interventions used in the included studies.We searched CENTRAL, the Cochrane Database of Systematic Reviews, MEDLINE, Embase, and four other databases up to 14 August 2018. There was no restriction on date, language, or publication status. We also searched ClinicalTrials.gov

2019 Cochrane

38. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Full Text available with Trip Pro

HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Observational and laboratory studies suggest that some hormonal contraceptive methods, particularly intramuscular depot medroxyprogesterone acetate (DMPA-IM), might increase women's susceptibility to HIV acquisition. We aimed to compare DMPA-IM, a copper intrauterine device (IUD (...) ), and a levonorgestrel (LNG) implant among African women seeking effective contraception and living in areas of high HIV incidence.We did a randomised, multicentre, open-label trial across 12 research sites in eSwatini, Kenya, South Africa, and Zambia. We included HIV-seronegative women aged 16-35 years who were seeking effective contraception, had no medical contraindications to the trial contraceptive methods, agreed to use the assigned method for 18 months, and reported not using injectable, intrauterine

2019 Lancet Controlled trial quality: predicted high

39. Screening for HIV Infection in Pregnant Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Full Text available with Trip Pro

Screening for HIV Infection in Pregnant Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Prenatal screening for HIV can inform use of interventions to reduce the risk of mother-to-child transmission. The US Preventive Services Task Force (USPSTF) previously found strong evidence that prenatal HIV screening reduced risk of mother-to-child transmission. The previous evidence review was conducted in 2012.To update the 2012 review on prenatal HIV (...) groups.One investigator abstracted data; a second checked accuracy. Two investigators independently rated study quality.Mother-to-child transmission; harms of screening and treatment; screening yield.Sixty-two studies were included in this review, including 29 new studies. There remains no direct evidence on effects of prenatal screening vs no screening on risk of mother-to-child HIV transmission, maternal or infant clinical outcomes, or the yield of repeat or alternative screening strategies. New

2019 JAMA

40. Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Full Text available with Trip Pro

Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Untreated HIV infection can result in significant morbidity, mortality, and HIV transmission. A 2012 review for the US Preventive Services Task Force (USPSTF) found antiretroviral therapy (ART) associated with improved clinical outcomes and decreased transmission risk in persons with CD4 cell counts less than 500/mm3.To update (...) the 2012 review on HIV screening to inform the USPSTF.Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews from 2012 to June 2018, with surveillance through January 2019.Nonpregnant individuals 12 years and older; randomized clinical trials (RCTs) and controlled observational studies of screening vs no screening, alternative screening strategies, earlier vs later initiation of ART, and long-term harms of ART.One investigator abstracted data

2019 JAMA